[Chinese expert consensus on the clinical application of recombinant human thrombopoiein and thrombopoiein receptor agonist (2023)].
出版信息
Zhonghua Xue Ye Xue Za Zhi. 2023 Jul 14;44(7):535-542. doi: 10.3760/cma.j.issn.0253-2727.2023.07.002.
Abstract
摘要
相似文献
1
[Chinese expert consensus on the clinical application of recombinant human thrombopoiein and thrombopoiein receptor agonist (2023)].重组人血小板生成素与血小板生成素受体激动剂临床应用中国专家共识（2023年）
Zhonghua Xue Ye Xue Za Zhi. 2023 Jul 14;44(7):535-542. doi: 10.3760/cma.j.issn.0253-2727.2023.07.002.
2
[Consensus on clinical diagnosis, treatment and prevention management of chemotherapy induced thrombocytopenia in China(2018)].《中国化疗所致血小板减少症临床诊断、治疗及预防管理专家共识（2018年版）》
Zhonghua Zhong Liu Za Zhi. 2018 Sep 23;40(9):714-720. doi: 10.3760/cma.j.issn.0253-3766.2018.09.014.
3
What's new in the management of chronic primary immune thrombocytopenia in adults and the use of thrombopoietin receptor agonists.成人慢性原发性免疫性血小板减少症的管理及血小板生成素受体激动剂的应用有哪些新进展？
Med Princ Pract. 2011;20(4):301-2. doi: 10.1159/000324876. Epub 2011 May 11.
4
Development of thrombopoietin receptor agonists for clinical use.用于临床的血小板生成素受体激动剂的研发。
J Thromb Haemost. 2009 Jul;7 Suppl 1:239-44. doi: 10.1111/j.1538-7836.2009.03440.x.
5
Comment on: Use of thrombopoietin receptor agonist (romiplostim) in neonatal autoimmune thrombocytopenia due to maternal immune thrombocytopenia.评论：血小板生成素受体激动剂（罗米司亭）在因母亲免疫性血小板减少症导致的新生儿自身免疫性血小板减少症中的应用。
Pediatr Blood Cancer. 2019 Jun;66(6):e27706. doi: 10.1002/pbc.27706. Epub 2019 Mar 11.
6
New drugs for familiar therapeutic targets: thrombopoietin receptor agonists and immune thrombocytopenic purpura.针对常见治疗靶点的新药：血小板生成素受体激动剂与免疫性血小板减少症
Eur J Haematol Suppl. 2008 Feb(69):9-18. doi: 10.1111/j.1600-0609.2007.00999.x.
7
[Management of refractory ITP with thrombopoietin receptor agonists].[血小板生成素受体激动剂治疗难治性免疫性血小板减少症]
Rinsho Ketsueki. 2011 Aug;52(8):627-32.
8
Use of romiplostim allows for hepatitis C therapy in a HIV/HCV coinfected patient.使用罗米司亭可使一名合并感染HIV/HCV的患者接受丙型肝炎治疗。
Ann Hematol. 2013 Jul;92(7):1001-2. doi: 10.1007/s00277-012-1659-z. Epub 2012 Dec 28.
9
Salvage therapy of autoimmune thrombocytopenic purpura revealing non-Hodgkin lymphoma by the thrombopoietin receptor agonist romiplostim.血小板生成素受体激动剂罗米司亭对自身免疫性血小板减少性紫癜的挽救治疗揭示了非霍奇金淋巴瘤。
Br J Haematol. 2012 Jan;156(1):145-7. doi: 10.1111/j.1365-2141.2011.08825.x. Epub 2011 Aug 16.
10
Use of peptide thrombopoietin receptor agonist romiplostim (Nplate) in a case of primary HIV-associated thrombocytopenia.肽类血小板生成素受体激动剂罗米司亭（Nplate）在一例原发性HIV相关血小板减少症中的应用。
J Int Assoc Provid AIDS Care. 2014 Jan-Feb;13(1):22-3. doi: 10.1177/2325957413502539. Epub 2013 Sep 13.
引用本文的文献
1
[ gene-related thrombocytopenia: a case report and literature review].[基因相关性血小板减少症：一例报告及文献综述]
Zhongguo Dang Dai Er Ke Za Zhi. 2025 Jun 15;27(6):723-730. doi: 10.7499/j.issn.1008-8830.2412065.
本文引用的文献
1
Avatrombopag for the treatment of thrombocytopenia induced by chemotherapy in patients with solid tumors: A multicenter, open-label, single-arm trial.阿伐曲泊帕用于治疗实体瘤患者化疗所致血小板减少症：一项多中心、开放标签、单臂试验。
Front Pharmacol. 2022 Sep 27;13:970978. doi: 10.3389/fphar.2022.970978. eCollection 2022.
2
Avatrombopag for the treatment of thrombocytopenia post hematopoietic stem-cell transplantation.阿伐曲泊帕用于治疗造血干细胞移植后的血小板减少症。
Ther Adv Hematol. 2022 Sep 28;13:20406207221127532. doi: 10.1177/20406207221127532. eCollection 2022.
3
Thrombopoietin receptor agonist discontinuation rates and reasons among patients with immune thrombocytopenia: a study of administrative claims linked with medical chart review.血小板生成素受体激动剂在免疫性血小板减少症患者中的停药率及停药原因：一项基于行政索赔数据并结合病历回顾的研究。
Ann Hematol. 2022 Sep;101(9):1915-1924. doi: 10.1007/s00277-022-04888-7. Epub 2022 Jul 18.
4
Exploring the Potential of Eltrombopag: Room for More?探索艾曲泊帕的潜力：还有更多空间吗？
Front Pharmacol. 2022 May 23;13:906036. doi: 10.3389/fphar.2022.906036. eCollection 2022.
5
A multicenter phase II study on the efficacy and safety of hetrombopag in patients with severe aplastic anemia refractory to immunosuppressive therapy.一项关于海曲泊帕对免疫抑制治疗难治的重型再生障碍性贫血患者疗效和安全性的多中心II期研究。
Ther Adv Hematol. 2022 Mar 30;13:20406207221085197. doi: 10.1177/20406207221085197. eCollection 2022.
6
Avatrombopag for chemotherapy-induced thrombocytopenia in patients with non-haematological malignancies: an international, randomised, double-blind, placebo-controlled, phase 3 trial.阿伐曲泊帕治疗非血液系统恶性肿瘤患者化疗引起的血小板减少症：一项国际、随机、双盲、安慰剂对照、3 期临床试验。
Lancet Haematol. 2022 Mar;9(3):e179-e189. doi: 10.1016/S2352-3026(22)00001-1.
7
Tapering and Discontinuation of Thrombopoietin Receptor Agonist Therapy in Patients with Immune Thrombocytopenia: Results from a Modified Delphi Panel.《免疫性血小板减少症患者的血小板生成素受体激动剂治疗的减量和停药：一项改良 Delphi 小组的研究结果》。
Acta Haematol. 2021;144(4):418-426. doi: 10.1159/000510676. Epub 2021 Mar 31.
8
Eltrombopag monotherapy can improve hematopoiesis in patients with low to intermediate risk-1 myelodysplastic syndrome.依鲁替尼单药治疗可改善低危至中危-1 级骨髓增生异常综合征患者的造血功能。
Haematologica. 2020 Dec 1;105(12):2785-2794. doi: 10.3324/haematol.2020.249995.
9
Eltrombopag preferentially expands haematopoietic multipotent progenitors in human aplastic anaemia.依鲁替尼可优先扩增人类再生障碍性贫血中的造血多能祖细胞。
Br J Haematol. 2021 Apr;193(2):410-414. doi: 10.1111/bjh.17140. Epub 2020 Nov 20.
10
Hemostatic changes by thrombopoietin-receptor agonists in immune thrombocytopenia patients.促血小板生成素受体激动剂对免疫性血小板减少症患者的止血作用改变。
Blood Rev. 2021 May;47:100774. doi: 10.1016/j.blre.2020.100774. Epub 2020 Nov 10.
Zotero 插件